Amide Proton Transfer weighted imaging:

**Advancement in molecular tumor diagnosis**

Kim van de Ven, PhD¹; Jochen Keupp, PhD²

¹Senior Clinical Scientist, Philips MR, ²Senior Scientist, Philips Research

Today, although MR is the gold standard in neuro-oncological imaging, its accuracy in tumor grading and treatment follow up assessment can be further improved. Amide Proton Transfer weighted (APTw) MRI is a new, unique, contrast-agent free brain MR imaging method that addresses the need for a more confident diagnosis in neuro oncology. It uses the presence of endogenous cellular proteins to produce an MR signal that directly correlates with cell proliferation, a marker of tumor activity. This white paper explains the main principles and general acquisition mechanism of APTw imaging as initially pioneered by the group of Dr. van Zijl and Dr. Zhou¹-⁴. It highlights how the Philips 3D APT product enables fast and robust APTw image acquisition by leveraging Philips unique patient adaptive MultiTransmit 4D and mDIXON XD TSE technologies, as well as supports easy viewing by using a dedicated color scale. Lastly, it explores how APTw imaging can support trained medical professionals in differentiating low grade from high grade gliomas and in distinguishing tumor progression from treatment effects in clinical practice.
Why is a new technique in neuro-oncology needed?

37% of non-enhancing gliomas are malignant, and although MRI is the gold standard for brain tumor treatment follow-up, current techniques are still not reliable enough to separate true progression from pseudo-progression.

In the treatment pathway subsequent to the diagnosis of a brain tumor, conventional MRI is regarded as the gold standard to evaluate treatment response. However, accurate classification of responders, non-responders or stable disease is a difficult task in radiology. One reason is that Gd-Ce MRI is a contrast based on blood-brain-barrier (BBB) disruption. Contrast-enhancement is a marker for aggressive tumor tissue, but also for many other non-tumorous processes, such as treatment-related inflammation, seizure activity, postsurgical changes, ischemia, acute radiation effects, and radiation necrosis. For example, conventional MRI often fails in differentiating necrotic tissue, e.g. as a radiation therapy treatment side effect, from recurring cancerous tissue. Because the BBB is disrupted in both cases.

Thus, an imaging marker that can non-invasively assess glioma grade, comprehensively characterize tumor heterogeneity, and discriminate treatment related necrosis from tumor recurrence in follow-up imaging examinations is highly desirable for an improved clinical practice. Amide Proton Transfer-weighted (APTw) imaging is sensitive to the concentration of amide protons contained in proteins and peptides, which are known to be elevated in high grade gliomas and in recurring tumors.

How does APT-weighted imaging yield a new contrast mechanism that can help clinicians with glioma grading and differentiate treatment effect from tumor progression?

APTw imaging is sensitive to the concentration of amide protons contained in proteins and peptides, which are known to be elevated in high grade gliomas and in recurring tumors.

What are the principles behind APT-weighted imaging?

While conventional MRI relies on the behavior of water protons in tissue. APTw imaging uses the signal of amide protons (NH group) contained in proteins and peptides. Protein/peptide levels are known to be particularly elevated in aggressive, highly proliferative tumor tissues and to be strongly correlated with the tumor grade, which is assessed on pathological features and defined by the World Health Organization (WHO grade). As a form of Chemical Exchange Saturation Transfer (CEST) imaging, APTw MRI exploits the fact that amide protons in small proteins/peptides constantly exchange with water protons in close spatial proximity (Please refer to Figure 1 for a schematic illustration). Because the amide protons have a different resonance frequency than the water protons, it is possible to selectively saturate the amide signal using radiofrequency (RF) irradiation tuned at a frequency of +3.5 ppm from the water resonance. When a water molecule is in close proximity to the amide group, the protons may exchange and carry over the nuclear spin saturation. In particular, the saturation is then found in the water signal that can be subsequently imaged by conventional means. When the saturation of the amide protons is maintained for about two seconds by continuous RF or pulsed RF, the final water saturation level is amplified due to accumulation of multiple proton saturation-exchange events. In addition, the resulting water saturation level is strongly correlated to the concentration of proteins/peptides in the tissue. The observed signal drop is then referred to as the APT signal.

Proteins with amide protons surrounded by water molecules are moving around. Saturation prepulse on protein’s amide proton frequency nulls MR signal of these protons. As a result of chemical exchange the nulled protons move from the protein to water molecules.

Figure 1: Illustration of the bio-physical principles of Amide Proton Transfer weighted (APTw) MRI based on chemical exchange. Protons (H) bound to proteins and peptides are saturated with a long, frequency-specific RF pulse. These saturated protons exchange with protons part of diffusing water (H2O), resulting in a signal reduction of the water signal which correlates with the local concentration of proteins and peptides.
How are APT-weighted images acquired?

The saturation of the water signal as described is the first step to obtain an APTw image. Subsequently, to generate reliable APTw imaging contrast, the so-called MTR asymmetry (MTR asym(\%)) is assessed. This requires the acquisition of a Z-spectrum, where a series of water signal levels is measured as a function of different frequency offsets, \( \Delta \omega \) (Figure 2). In such a spectrum, the water signal saturation is measured as a function of saturation frequency. For convenience, the water frequency (normally around 4.75 ppm in the proton MR spectrum) is placed at 0 ppm, and drops to a minimum at \(-3.5\) ppm, since at this point, the RF pulse directly saturates the water protons. In order to distinguish the APT signal from several background effects (e.g. direct water saturation and magnetization transfer contributions from semi-solid tissue components such as membranes), an MTR asymmetry analysis (symmetry with respect to the water frequency) is performed based on a voxel-by-voxel analysis.

First, the Z-spectrum is aligned per voxel using information on local magnetic field variation (B_0 field map) such that the maximum direct water saturation is found exactly at 0 ppm. Next, the asymmetry is evaluated by subtracting the positive frequency side \( S_+ \) from the negative side \( S_- \) and normalized to an unsaturated image \( S_0 \). (See equation 1). The resulting MTR asym value at +3.5 ppm is displayed as a percent level (relative to \( S_0 \)) in the final APTw image, and referred to as APTw%. (Equation 2).

\[
\text{MTR asym(\%)} = \frac{S_+ - S_-}{S_0} \times 100
\]

\[
\text{APTw\%} = \text{MTR asym(\%)} = \frac{S_+ + S_-}{S_0} \times 100
\]

How is optimal APT-weighted imaging enabled by patient-adaptive MultiTransmit 4D?

APTw imaging creates a molecular image contrast, which relies on very delicate imaging principles and correct parameter settings. Using the Philips unique dual transmit system with patient-adaptive RF shimming⁴, optimal contrast is achieved between tumor tissue and brain parenchyma by continuously saturating the proton spins at a selective frequency for about two seconds using an RF pulse train⁵. In conventional imaging, two independent RF sources are used simultaneously and adjusted by phase and amplitude (A1, A2) to homogenize the image intensity in a patient adaptive way. In Philips APTw imaging, the patient-adaptive RF shimming mechanism is used to drive the RF amplifiers in an alternating fashion by carefully tuning the source amplitudes A1 and A2 for each patient, such that continuous and uniform two-second-long RF saturation is achieved (Figure 3). The contributions of the two channels add up over time and lead to spatially homogeneous saturation. In APTw sequences, two different RF shims settings are used in parallel, one for image homogeneity via the imaging pulses like excitation or refocusing, and a different shim set for RF saturation, building a robust and homogeneous APTw contrast. Without dual-transmit, RF saturation pulses for APTw MRI are typically limited to 800 ms or less⁶.
How does mDIXON XD TSE shorten the acquisition of APT-weighted images?

APTw MRI examinations in 3D may be very time-consuming, because multiple imaging volumes need to be acquired for different RF saturation frequency offsets. Keeping the acquisition time within a clinically acceptable duration of 3-5 minutes while providing suitable robustness, signal-to-noise ratio and spatial resolution further guide the choice of APT imaging parameters. The Philips implementation leverages two major principles to allow an acceptable scan time. First, it does not acquire an extensive Z-spectrum, but only nine image volumes at critical frequencies for the Z-spectrum. Second, a \( B_0 \) field map acquisition for the asymmetry calculation can be derived from three acquisitions at +3.5 ppm using the mDIXON algorithm17,18.

Figure 4 contains a schematic representation of the Philips implementation, in total nine image volumes are acquired at seven different frequency offsets, using a 3D TSE read-out and Lagrange interpolation19 among the different saturation frequencies. The non-saturated \( S_0 \) image is acquired with a large offset of 3.5 ppm on both sides of the Z-spectrum. This allows calculation of a \( B_0 \) field map directly from the APTw image acquisition based on mDIXON algorithms. This \( B_0 \) field map is used for the \( B_1 \) correction to allow calculation of APTw% on a voxel-by-voxel basis. With this approach, no separate \( B_1 \) field map or separate Z-spectrum acquisition (WASSR 20) is needed because the \( B_1 \) field information was obtained simultaneously. As \( B_1 \) fields may change due to physiological or drift effects during or after the APT image acquisition, the integrated \( B_1 \) mapping approach using mDIXON approach provides enhanced robustness to these \( B_1 \) field alterations.

Fast integrated \( B_0 \) correction

How does the dedicated APT-weighted image color scale simplify interpretation?

APTw images are shown in a rainbow-type color scale ranging from green (0% APTw%) to red (5% APTw%). This scale is standardized across all APTw images to facilitate fast and easy reading, as well as to enable comparison among hospitals or between pre- and post-treatment images. The advanced reconstruction algorithm combines all information and generates the final color-coded APTw image volumes, using APTw% and a standardized scale of \( \pm 5\% \) for display. As additional anatomical reference, imaging reconstruction also provides an \( S_0 \) image volume.

For tumor grading, normal white and grey matter typically appear green, white areas of APTw hyper intensities, appearing yellow or red, may indicate solid tissue areas of grade III and IV gliomas. For treatment follow-up, normal white and grey matter and treatment necrosis typically appear grey, while areas of APTw hyper intensities, appearing yellow or red may indicate tumor recurrence in solid tissue areas. Adhering to routine radiology procedures, all acquired image contrasts are viewed in concert, aiding identification of potential solid tumor areas via anatomical T1w, T2w and/or fluid-enhanced FLAIR images that can be scored for APTw hyper-intensity (yellow/red) to assist tumor grading.

In the literature on APTw MRI, it is common to show brain images in which the skull and the fat around the skull have been removed. Skull stripping is not performed for APTw imaging on the system, because such algorithms are often not reliable and could potentially conceal tumor tissue for example near the cortex. Thus, a colored rim related to fatty tissue in the skull may be visible around the brain, which is visually distinct from the relevant brain areas and is easily disregarded during the radiological reading process. For ROI-based measurements on APTw images it is important to note that the contrast should be assessed using the difference between normal appearing brain (white or grey matter, preferably contra-lateral to the lesion) and tumor tissue values, which is called SMTR_17,20. The APTw technique may show a small overall offset - less than 0.5% APTw% - if comparing absolute APTw% values, therefore it is important to follow the procedures described in the literature for ROI definitions in grading applications. Furthermore the highest tumor grade found in sub-regions of the lesion is the determinant for the overall grade. Thus, in the literature17,20, several small regions of interest (ROI) were defined on APTw images guided by the highest levels of APTw contrast observed in solid parts of the lesion. Alternatively, a histogram can be calculated within a large ROI including the tumor region and the highest grade shown by APTw contrast is assessed via the 90-percentile of the signal distribution21.

Besides gliomas, other lesion types - in particular meningiomas, lymphomas22, and metastases21 - may be depicted as APTw hyper-intensity, however to date there is insufficient evidence to understand the implications of high APTw signals in these pathologies. Furthermore, fatty tissues or tissue fluids, for example cysts, blood vessels or hemorrhage, may show up as APTw hyper-intensity due to their high protein content. It is therefore of utmost importance to read the APTw images carefully and always in combination with images from a standard multi-parametric tumor protocol.
What are the clinical benefits of APT-weighted imaging?

APTw imaging helps to differentiate between low grade and high grade gliomas and to differentiate between treatment effect and tumor progression.

APTw imaging is a new MR imaging contrast in brain tumor imaging. Because of its unique capability to assess the molecular composition of the tissue, it provides new information in addition to regular, multi-parametric tumor imaging protocols.

Some of the clinical studies using APTw imaging address pre-operative characterization of gliomas, focusing on imaging-based assessment of the tumor grade. It has been demonstrated that APTw imaging correlates with the histopathological grade of a tumor specimen, often in conjunction to conventional imaging, perfusion and diffusion MRI.

Case 1 shows examples of the appearance of APTw images in different tumor grades. One should also be aware that histopathological grading according to the 2007 WHO guidelines for classification of tumors of the central nervous system has been used in all of these studies. In the 2016 update of these guidelines the advice is to predominantly classify brain tumors based on genetic profile (IDH status) rather than on histopathological features. The first study with APTw imaging based on these new guidelines shows promising results in being able to discriminate IDH wild-type from IDH mutation in histopathology based grade II tumors.

In addition to pre-operative grading, some studies used APTw imaging to assess the tumor heterogeneity and therefore guide surgical procedures to remove the most malignant parts of the tumor for further analysis. This assessment will decrease the chance that the malignancy of a tumor is underestimated due to an inappropriate biopsy location. Case 2 demonstrates the use of APTw imaging for biopsy guidance, as well as the correlation between the histopathological assessment (cell count and Ki-67 staining) of excised tumor tissue with APTw values.

Very important applications of APTw imaging are expected in the post-treatment domain. It is standard practice to perform surgical resection of the tumor, followed by chemo- and radiation therapy. Subsequently the patient receives MRI scans as part of treatment follow-up. However, there can be significant changes to the tumor area and the surrounding brain tissue due to the treatment. Thus, it is difficult to discriminate treatment-induced effects, such as pseudo-progression and radiation necrosis, from true tumor recurrence. Several studies have shown that APTw imaging is superior in discriminating between treatment-induced effects and true tumor progression, whether or not in conjunction with conventional MR imaging contrasts as well as more advanced methods such as perfusion (DSC and DCE) and spectroscopy. Cases 3, 4 and 5 are exemplary for the added value of APTw imaging in the post-surgical phase.

CASE 1: Differentiation of low-grade from high-grade gliomas is facilitated by APTw imaging

Patient 1: 38-year-old patient with confirmed diffuse astrocytoma, WHO grade II, IDH-1 mutant, MIB-1 index 4.4%. In this case, both conventional and APTw images indicated low-grade glioma. APTw images were useful for the confirmation. The tumor was surgically resected, and the patient is still alive without a recurrence for 3 years.

Patient 2: 47-year-old patient, anaplastic astrocytoma, WHO grade III, IDH-1 mutant, MIB-1 index 7.1%. In this case, preoperative grading by conventional MRI was difficult since the lesion showed only a slight enhancement after a Gd administration. However, APTw images showed high APTw signals, which indicated high-grade glioma. This was a recent case and no follow-up studies were performed yet.

Patient 3: 56-year-old patient, glioblastoma, WHO grade IV, IDH-wild type, MIB-1 index 39.7%. The APTw image was useful for the determination of the location of biopsy. Since the tumor showed high signal intensity throughout the tumor on APTw images, it was considered that biopsy can be performed in any parts of the lesion. This was a recent case and no follow-up studies were performed yet.
CASE 2: APTw signal correlates with histopathology of biopsy sites

Courtesy: Johns Hopkins University, Baltimore, USA. Dr. S. Jiang, Dr. J. Zhou & Dr. P.C.M. van Zijl.

Two cases of patients with different types of tumors, pre- and post-treatment.

Patient 1: APTw imaging can depict tumor progression: A 34-year old patient diagnosed with anaplastic astrocytoma, IDH-mutant. A contrast-enhancing mass located at the posterior aspect of the surgical cavity. The patient received temozolomide as the second line treatment, but the tumor progressed. Note prominent increase in the APTw value on APTw imaging on the follow up.

Patient 2: APTw imaging can become an early biomarker for antiangiogenic treatment: A 30-year old patient diagnosed with glioblastoma, IDH-wildtype from the stereotactic biopsy. There is an irregular-shaped, contrast-enhancing mass in the bilateral hypothalamus. The patient has treated with three cycles of antiangiogenic treatment (bevacizumab, Avastin). Though conventional MR imaging showed equivocal decrease in the contrast-enhanced T1-weighted imaging or fluid-attenuated inversion recovery, APTw imaging showed prominent decrease in the value within the tumor solid portion. The tumor stabilized during the follow-ups.

Conventional MR, APTw MR, and microscopic images for a patient with a histopathologically confirmed glioblastoma in the right parietal lobe. (A) Conventional MR images demonstrate a peripherally Gd-enhancing mass with central coagulative necrosis (showing T2w hypointensity and substantially suppressed water signals on FLAIR image), as well as mild adjacent vasogenic oedema. The APTw image shows hypointensity in the Gd-enhancing area, compared to contralateral, normal appearing tissues. (B) Stereotactic site on the clinically obtained Gd-T1w images. One specimen was obtained from the rim of the tumour (with Gd enhancement and clear APTw hyperintensity). (C) Microscopic examination revealed extremely high cellularity (2468/FOV), prominent proliferation, and mitotic activity (Ki-67 of 22.3%), as well as the vascular proliferation typical of glioblastoma. APTw imaging intensities of individual specimens and correlation analysis with histopathology indices: the correlation analysis results (C) between APTw intensities and cell count, as well as (D) between APTw intensities and Ki-67 index. This graph is reproduced from Jiang et al. with permission of the publisher.

CASE 3: APTw imaging helps to assess treatment effectiveness

Courtesy: ASAN Medical Center, Seoul, South-Korea. Dr. J.E. Park & Dr. H.S. Kim

Two cases of patients with different types of tumors, pre- and post-treatment.

Patient 2: APTw imaging can become an early biomarker for antiangiogenic treatment. A 30-year old patient diagnosed with glioblastoma, IDH-wildtype from the stereotactic biopsy. There is an irregular-shaped contrast-enhancing mass in the bilateral hypothalamus. The patient has treated with three cycles of antiangiogenic treatment (bevacizumab, Avastin). Though conventional MR imaging showed equivocal decrease in the contrast-enhanced T1-weighted imaging or fluid-attenuated inversion recovery, APTw imaging showed prominent decrease in the value within the tumor solid portion. The tumor stabilized during the follow-ups.
CASE 4: APTw imaging shows post-surgical tumor recurrence in a metastatic brain lesion

A ten-year-old patient underwent Ewing’s sarcoma tumor resection 7 years ago, but was found to now have a large metastatic lesion in the brain. This lesion shows clearly increased APTw signal.

Immediately post-resection, MRI was again performed. T2-weighted and postcontrast T1-weighted images are quite inconclusive for distinguishing residual tumor tissue from postoperative tissue changes. On the APTw image some high signal is still seen, which would suggest residual tumor tissue.

In later follow-up scans the post-contrast T1-weighted images suggest recurrent tumor growth. It would be interesting to study the predictive value of APTw imaging in a large patient group.

A 52-year-old male patient had a progressive impairment in his right field of vision. Upon neurological examination, a hemianopsia to the right and mild psychomotor slowing was noted. Otherwise, clinical examination was normal.

MRI demonstrated a centrally necrotic tumor in the left occipital lobe with extensive perifocal FLAIR-hyperintense edema. CBV was markedly increased, speaking to a high-grade glioma (pre-operative MRI).

Following gross total resection of the contrast-enhancing tumor, a pathological diagnosis of a WHO grade IV glioblastoma, IDHwt, MGMT promoter methylated was made. According to the Stupp protocol, a combined radio-chemotherapy with temozolomide was begun, which was well tolerated.

However, the MRI routinely taken four weeks after completion of the radiotherapy showed a strong linear enhancement along the resection cavity as well as a newly occurred, contrast-enhancing nodule just lateral to it. CBV here was only slightly increased. APTw imaging on the other hand showed a strong hyperintensity in this area (see post-treatment images). In our interdisciplinary tumor board, a decision for surgery was made. In good agreement with the APTw imaging, pathological analysis found many vital glioblastoma cells and only minor (therapy-associated) necrosis. This clinical case demonstrated the importance of APTw imaging in distinguishing necrosis caused by treatment effect from tumor progression.

CASE 5: Glioblastoma recurrence after surgery detected on APTw images

A ten-year-old patient underwent Ewing’s sarcoma tumor resection 7 years ago, but was found to now have a large metastatic lesion in the brain. This lesion shows clearly increased APTw signal.

Immediately post-resection, MRI was again performed. T2-weighted and postcontrast T1-weighted images are quite inconclusive for distinguishing residual tumor tissue from postoperative tissue changes. On the APTw image some high signal is still seen, which would suggest residual tumor tissue.

In later follow-up scans the post-contrast T1-weighted images suggest recurrent tumor growth. So, it would be interesting to study the predictive value of APTw in a large patient group.

However, the MRI routinely taken four weeks after completion of the radiotherapy showed a strong linear enhancement along the resection cavity as well as a newly occurred, contrast-enhancing nodule just lateral to it. CBV here was only slightly increased. APTw imaging on the other hand showed a strong hyperintensity in this area (see post-treatment images). In our interdisciplinary tumor board, a decision for surgery was made. In good agreement with the APTw imaging, pathological analysis found many vital glioblastoma cells and only minor (therapy-associated) necrosis. This clinical case demonstrated the importance of APTw imaging in distinguishing necrosis caused by treatment effect from tumor progression.
Future of APT-weighted imaging

In the future, APT imaging may become beneficial in pediatric tumor exams as an alternative to contrast-enhanced scans that are frequently used for long-term disease management, which are under scrutiny for possible negative side effects, especially in young subjects. It remains to be shown for this young patient cohort that APT imaging can reliably detect tumor recurrence or progression for the relevant tumor sub-species and thereafter replace post-contrast scans.

In addition to APT imaging of brain tumors, there are other promising applications of this new MR contrast mechanism in particular, stroke tissue may be characterized based on pH effects of ischemic acidosis, which was the very first proposed application of APT imaging.22 For APT imaging of brain tissue, an optimal exchange with oxygen water protons. Furthermore, the same 2-z-spectrum acquisition with an integrated, mDIXON-based, B map allows for robustness against B field fluctuations during the measurement. Lastly, APT imaging is primarily standardized, a fixed, color scale

References